Αρχική World News Maintenance Rucaparib for Platinum-Sensitive Pancreatic Adenocarcinoma with HRD-Associated Mutations

Maintenance Rucaparib for Platinum-Sensitive Pancreatic Adenocarcinoma with HRD-Associated Mutations

Maintenance rucaparib is a safe and effective treatment for patients with platinum-sensitive pancreatic adenocarcinoma and germline or somatic pathogenic variants in BRCA1/2 or PALB2. Dr Kim A. Reiss of the Abramson Cancer Center, Perelman School of Medicine, and Department of Medicine, University of Pennsylvania in Philadelphia, PA, US and colleagues observed activity in patients with germline PALB2 pathogenic variants and somatic BRCA2 pathogenic variants and in a patient with squamous cell carcinoma, suggesting that the role of poly ADP-ribose polymerase (PARP) inhibitors might be expanded in clinical practice. The study team published the findings on 10 May 2021 in the Journal of Clinical Oncology.

Patients with pancreatic adenocarcinoma and pathogenic germline BRCA1/2 and PALB2 alterations are sensitive to platinum chemotherapy. Olaparib, the PARP inhibitor is approved by US Food and Drug Administration as maintenance treatment for patients with germline BRCA1/2 pathogenic variants and platinum-sensitive, metastatic pancreatic adenocarcinoma. There is a need to expand the group of patients who may benefit from PARP inhibition beyond those with germline BRCA pathogenic variants.

Recent study demonstrated that patients with metastatic breast cancer and germline PALB2 or somatic BRCA pathogenic variants benefit from olaparib. Previous studies in prostate and ovarian cancer have shown activity of PARP inhibitors in patients with homologous recombination deficiency (HRD) beyond germline BRCA pathogenic variants.

The authors wrote in the study background that it is critical to refine clinical and biological biomarkers that might predict for benefit from PARP inhibition in patients with pancreatic adenocarcinoma. They designed a single-arm phase II study to test the hypothesis that maintenance treatment with rucaparib in patients with platinum-sensitive advanced pancreatic adenocarcinoma and a germline or somatic pathogenic variant in BRCA1/2 or PALB2 can result in progression-free survival (PFS) rate at 6 months (PFS6) of at least 60%.

Eligible patients received at least 16 weeks of platinum-based chemotherapy without evidence of platinum resistance. Chemotherapy was discontinued and patients received rucaparib until progression. The primary endpoint was the PFS6. Secondary endpoints included safety, overall response rate (ORR), disease control rate (DCR), duration of response (DoR), and overall survival (OS).

Of 46 enrolled patients, 42 were evaluable, of whom 27 with germline BRCA2, 7 with germline BRCA1, 6 with germline PALB2 and 2 with somatic BRCA2.

The PFS6 was 59.5% (95% confidence interval [CI] 44.6 to 74.4). Median PFS was 13.1 months (95% CI 4.4 to 21.8), and median OS was 23.5 months (95% CI 20 to 27). The PFS at 12 months was 54.8%.

The ORR in the 36 patients with measurable disease was 41.7% with 3 complete responses and 12 partial responses (95% CI 25.5 to 59.2); DCR was 66.7% (95% CI 49.0 to 81.4). Median DoR was 17.3 months (95% CI 8.8 to 25.8).

Responses occurred in 11 of 27 patients with germline BRCA2 (41%), 3 of 6 patients with germline PALB2 (50%) and in 1 of 2 patients with somatic BRCA2 (50%).

No new safety signals were observed.

The authors wrote that the results of their study provide promising evidence, complementing and furthering findings reported in the POLO study, that PARP inhibition may be an effective maintenance treatment for a broader range of patients with pancreatic adenocarcinoma with both, somatic and germline HRD–associated mutations.

This investigator-initiated study was supported by Clovis Oncology.

Reference

Reiss KA, Mick R, O’Hara M, et al. Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1BRCA2, or PALB2. JCO; Published online 10 May 2021. DOI: 10.1200/JCO.21.00003.

Source

Προηγούμενο άρθροChecking in on our Mental Health
Επόμενο άρθρο5 Tips to Move Beyond the Bedside

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Overall Breast Cancer Incidence Down Since 1999, Rates Increase for Women Under 40

U.S. breast cancer death rates decreased by about 1% per year between 2013 and 2018. What were the new case rates during that same...

Impressive Responses to PD-1 Blockade in a Large Cohort of Children and Young Adults with Recurrent/Progressive Germline DNA Replication Repair-Deficient Cancers

A large, observational, registry-based study that leveraged systematically collected data gathered both retrospectively and prospectively through the International Replication Repair Deficiency Consortium reveals impressive...

2-Year-Boy Is So Excited To See Himself In Disney’s ‘Encanto’

The importance of representation in media has been a growing topic of concern, and companies have responded by adding more diversity to their characters,...

Man Walks Entire Continent To Spread Awareness About Mental Health & Suicide Prevention

Matthew Fennell is walking over 3,000 miles across Australia for an important cause and one that is near and dear to his heart. Last year,...

Boy Battling Cancer Becomes Honorary Police Officer, Sworn In To 45 Agencies

At just ten years old, Devarjaye “DJ” Daniel has already been through more than most people go through in their entire lives. DJ has been...

Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide for the Treatment of Patients with Uterine Carcinosarcoma

With regard to overall survival (OS), paclitaxel and carboplatin was not inferior and demonstrated improved progression-free survival (PFS) when compared with paclitaxel and ifosfamide...